← Leaderboards
Benjamin Joseph Murdock
University Of Michigan At Ann Arbor
$2,524,630
Attributed
$4,261,790
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,974,321 · 1
ATSDR$1,287,469 · 2
By mechanism
R01$3,761,790 · 2
U01$500,000 · 1
Top collaborators
- Stephen Goutman6 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Eva L Feldman$26,770,746
- Stephen Goutman$5,836,753
- Stuart A Batterman$13,600,215
- Sami Barmada$8,649,535
- Kirsten L Gruis$953,100
Others in their field
Other Emerging Leaders on “Disease Progression”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$111,936,677
- Klaus Romero · Critical Path Institute$90,404,592
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$45,424,821
- Ryan Cirz · Revagenix, Inc.$40,209,479
Research focus
Disease ProgressionAls PatientsAffectAmyotrophic Lateral Sclerosis TherapyAnimalsAreaAmyotrophic Lateral SclerosisBiobankBiological MarkersBloodBlood SpecimenCd4 Positive T LymphocytesCell CountCellsCessation Of LifeCharacteristicsClinical TrialsCoculture TechniquesCohortCytotoxicityData SetDeep Neural NetworkDesignDrug Development
Grant awards (9)
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$515,683
R01 · FY2025 · NS
Spectral flow cytometry identifies new immune signatures that provide personalized ALS risk and progression biomarkers and therapeutic targets$500,000
U01 · FY2025 · TS
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$568,145
R01 · FY2024 · NS
RFA-TS-22-001: Interactions between the microbiome, metabolome, and immune system as underlying mechanisms of ALS pathogenesis$300,000
R01 · FY2024 · TS · contact PI
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$613,303
R01 · FY2023 · NS
Interactions between the microbiome, metabolome, and immune system as underlying mechanisms of ALS pathogenesis$187,469
R01 · FY2023 · TS · contact PI
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$633,717
R01 · FY2022 · NS
Interactions between the microbiome, metabolome, and immune system as underlying mechanisms of ALS pathogenesis$300,000
R01 · FY2022 · TS · contact PI
Creating a foundation for personalized age- and sex-based immune-targeted therapies from an ALS longitudinal cohort by identifying peripheral and central immune signatures$643,473
R01 · FY2021 · NS